Old Web
English
Sign In
Acemap
>
authorDetail
>
Xianchen Liu
Xianchen Liu
Bristol-Myers Squibb
Atrial fibrillation
Apixaban
Diabetes mellitus
Medicine
Internal medicine
2
Papers
8
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
ESTIMATING THE LIFETIME CLINICAL BENEFITS OF APIXABAN VERSUS CURRENT STANDARD OF CARE REGIMEN IN A UNITED STATES NON-VALVULAR ATRIAL FIBRILLATION POPULATION SIMILAR TO THAT ENROLLED IN ARISTOTLE AND AVERROES
2014
Journal of the American College of Cardiology
Hemant Phatak
Paul Dorian
Thitima Kongnakorn
Tereza Lanitis
Andreas Kuznik
Jack Mardekian
Xianchen Liu
Jack Lawrence
Gregory Y.H. Lip
Show All
Source
Cite
Save
Citations (0)
REAL WORLD DISCONTINUATION RATES WITH APIXABAN VERSUS WARFARIN, DABIGATRAN, OR RIVAROXABAN AMONG ATRIAL FIBRILLATION PATIENTS NEWLY INITIATED ON ANTICOAGULATION THERAPY: EARLY FINDINGS
2014
Journal of the American College of Cardiology
Xianying Pan
Sumesh Kachroo
Xianchen Liu
Hugh Kawabata
Hemant Phatak
Show All
Source
Cite
Save
Citations (8)
1